Scribe Therapeutics Inc. SCTX
17.36 USD +0.68 (+4.08%)
At closeNov 10, 2026, 4:01 PM EST
17.36 0.00 0.00%
After hours · Nov 10, 4:01 PM ET
16.01 Day range 18.30
15.41 52-week range 37.25
- YTD
- -8.49%
- 1 year
- -8.49%
- Market cap
- 328.65M
- EPS (ttm)
- -4.00
- YTD return
- -8.49%
- 1-year return
- -8.49%
- Volume
- 343.28K
- Avg volume
- 385.94K
- Open
- 16.42
- Previous close
- 16.68
- Day's range
- 16.01 – 18.30
- 52-week range
- 15.41 – 37.25
5D +0.71 (+4.45%)
Financials — quick view
SCTX Revenue — quarterly 1.92M
SCTX Net income — quarterly -6.48M
SCTX EPS — quarterly -2.62
News
Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences 
Scribe Therapeutics To Present Data In American Heart Association’s Scientific Sessions On Its Three Clinical Programs 
Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026 
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought 
Scribe Therapeutics: Underrated In-Vivo Gene Therapy Developer With Near-Term Catalyst 
Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday 
Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
Scribe Therapeutics Inc. (NASDAQ:SCTX) Stock Rated “Moderate Buy” by Wall Street Analysts 
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
Your note
Sign in to keep a note on SCTX — it syncs with the Stock Master app.